Core Insights - The CREST-2 study demonstrated that carotid artery stenting combined with intensive medical therapy significantly reduces the risk of stroke compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis [1][2][4] - The study results were presented at major medical conferences and published in the New England Journal of Medicine, marking a pivotal moment for the treatment of carotid disease [1][4] Study Details - CREST-2 was a NIH-sponsored clinical trial involving 155 centers globally, comparing outcomes of carotid artery stenting plus intensive medical management against intensive medical management alone [4] - The primary outcome measured was a composite of any stroke or death, assessed from randomization to 44 days, or ipsilateral ischemic stroke during the follow-up period of up to 4 years [4] - A total of 1245 patients were randomized in the stenting trial, while 1240 patients were randomized in the endarterectomy trial [4] Company Positioning - InspireMD's CGuard Prime carotid stent system is positioned as a leading option for carotid stenting, supported by the positive CREST-2 results and over 65,000 global implants [3][5] - The company emphasizes the effectiveness of its MicroNet™ mesh technology in achieving low adverse event rates, with a reported 1.93% major adverse event rate through 12 months in high surgical risk patients [3]